Metabolic lessons from the study of young adolescents with polycystic ovary syndrome - Is insulin, indeed, the culprit?

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 10, 2000, Pages 3520-3525

  Oberfield, Sharon E ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN;

ADOLESCENT; ADULT; ANOVULATION; COMORBIDITY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EDITORIAL; FEMALE; GASTROINTESTINAL SYMPTOM; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPERINSULINISM; INSULIN METABOLISM; INSULIN RESISTANCE; INSULIN RESPONSE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL;

EID: 0033766626     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.85.10.6959     Document Type: Editorial

References (56)

1. Genetics of non-insulin dependent (type II) diabetes mellitus
2. Obesity and glucose intolerance in androgen excess
3. Assessment of insulin resistance
4. Insulin action in the polycystic ovary syndrome
5. The insulin-related ovarian regulatory system in health and disease
6. Serine phosphorylation of human P450c17 increases 17,20-lyase activity; implications for adrenarche and the polycystic ovary syndrome
7. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and skeletal muscle
8. The regulation of human P450c17 activity: Relationship to premature adrenarche, insulin resistance and the polycystic ovary syndrome
9. 17,20 Lyase activity in cultured fibroblasts stably expressing P450c17: No difference between patients with polycystic ovary syndrome and normal subjects
10. Dysregulation of cytochrome P450c17α as a cause of polycystic ovarian syndrome
11. Decreases in ovarian cytochrome P450c17α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome
12. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17α activity and serum androgens
13. Insulin infusion amplifies 17α-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: Apparent relative impairment of 17,20-lyase activity
14. Insulin enhancement of luteinizing hormone and follicle-stimulating release by cultured pituitary cells
15. Insulin-like growth factors as intraovarian regulators of granulosa cell growth and function
16. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome
17. Puberty and polycystic ovarian syndrome; the insulin/insulin-like growth factor I hypothesis
18. Insulin resistance in prepubertal African-American and Hispanic girls with premature adrenarche: A risk factor for polycystic ovary syndrome
19. Fasting glucose to insulin ratio (FGIR) is a simple measure of insulin resistance in young girls with premature adrenarche (PA) or obesity
20. The roles of insulin sensitivity, insulin-like growth factor I (IGF-I), and IGF-binding protein-1 and -3 in the hyperandrogertism of African-American and Caribbean Hispanic girls with premature adrenarche
21. Postpubertal outcome in girls diagnosed of premature pubarche during childhood: Increased frequency of functional ovarian hyperandrogenism
22. Hyperinsulinemia and decreased insulin-like growth factor-binding protein-1 are common features in prepubertal and pubertal girls with a history of premature pubarche
23. Anovulation after precocious pubarche: Early markers and time course in adolescence
24. Hyperinsulinaemia, dyslipaemia and cardiovascular risk in girls with a history of premature pubarche
25. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): Relation to reduced fetal growth
26. Insulin resistance early in adulthood in subjects born with intrauterine growth retardation
27. Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: Relation to reduced fetal growth
28. Precocious pubarche, dyslipidemia, and low IGF binding protein-1 in girls: Relation to reduced prenatal growth
29. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea and hyperinsulinism after precocious pubarche
30. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism
31. Stimuation of the intracellular portion of the human receptor by the antidiabetic drug metformin
32. Metformin associated lactic acidosis (MALA) in a patient with normal renal function
33. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy
34. Can metformin reduces insulin resistance in polycystic ovary syndrome
35. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome
36. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a) and immunoreactive insulin levels in patients with the polycystic ovary syndrome
37. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome
38. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome
39. Effects of metformin on gonadodtropin-induced ovulation in women with polycystic ovary syndrome
40. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome
41. Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhoea
42. Effects of metformin on adrenal stroidogenesis in women with polycystic ovary syndrome
43. Administration of metformin to a diabetic woman with extreme hyperandrogenemia of nontumoral origin: Management of infertility and prevention of inadvertent masculinization of a female fetus
44. Effect of metformin on insulin-like growth factor (IGF) I and IGF-binding protein I in polycystic ovary syndrome
45. Metformin treatment reduces cytochrome P-450c117α response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome
46. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: A randomized, double-blind, placebo controlled 6-month trial, followed by open, long-term clinical evaluation
47. Metformin treatment reduces endothelin-1 and androgen levels and improves insulin-resistance in women with polycystic ovary syndrome
48. Weight reduction and sustained weight loss with metformin and carbohydrate modified diet in the treatment of nondiabetic women with midlife weight gain and hyperinsulinemia
49. Metformin increases the ovulatory response to clomiphene citrate in patients resistant to CC alone
50. Metformin improves menstrual regularity and hyperandrogenemia in adolescents with polycystic ovary syndrome
51. A therapeutic trial of metformin in obese adolescents predisposed to type 2 diabetes mellitus
52. Combined oral contraceptive treatment of adolescent girls with polycystic ovary syndrome
53. Insulin sensitizers and antiandrogens in the treatment of polycystic ovary syndrome
54. Relationships of insulin and intact and split proinsulin to haemostatic funstion in young men with and without coronary artery disease
55. Intrauterine growth of live-born Caucasian infants at sea level: Standards obtained from measurements in 7 dimensions of infants born between 25 and 44 weeks of gestation
56. Type 2 diabetes in children and adolescents. Consensus statement